PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026ESMO Open0 citationsOpen Access

4P Real-world outcomes of a trastuzumab emtansine (T-DM1) biosimilar (Ujvira) in early-stage HER2-positive breast cancer: A single-centre retrospective study from India

View Full Paper
KPK.B. Patel

Key Points

  • This study aims to evaluate the real-world outcomes of a T-DM1 biosimilar in early-stage HER2-positive breast cancer patients, focusing on invasive disease-free survival and safety.
  • Conducted as a retrospective study at a single centre in India.
  • Evaluated outcomes of a trastuzumab emtansine biosimilar after neoadjuvant therapy.
  • Assessed key metrics such as invasive disease-free survival (IDFS) and safety.
  • Found improvements in invasive disease-free survival (IDFS) with the T-DM1 biosimilar.
  • Noted acceptable safety outcomes in routine clinical practice.
  • Results indicate potential benefits for patients in low-resource settings.

Abstract

In the KATHERINE trial, adjuvant trastuzumab emtansine (T-DM1) significantly improved invasive disease-free survival (IDFS) in patients with residual HER2-positive breast cancer following neoadjuvant therapy. Real-world data on T-DM1 biosimilars in the post-neoadjuvant setting remain limited, particularly in low- and middle-income countries. This study evaluated IDFS and safety outcomes of a T-DM1 biosimilar in routine Indian clinical practice.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

K.B. Patel (2026) studied this question.

synapsesocial.com/papers/69cf5cd15a333a821460a68dhttps://doi.org/10.1016/j.esmoop.2026.106107
Ask AI
Helpful
Bookmark
Share
View Full Paper